Ying Pang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11544257/publications.pdf

Version: 2024-02-01

28	640	623734	642732
papers	citations	14 h-index	23 g-index

28	28	28	1073
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget, 2017, 8, 56110-56125.	1.8	64
2	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	2.4	60
3	Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2018, 24, 3423-3432.	7.0	57
4	Calcium Signaling Involvement in Cadmium-Induced Astrocyte Cytotoxicity and Cell Death Through Activation of MAPK and PI3K/Akt Signaling Pathways. Neurochemical Research, 2015, 40, 1929-1944.	3.3	56
5	Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. , 2018, 188, 168-175.		40
6	Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. Cancers, 2019, 11, 436.	3.7	33
7	Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. Oncotarget, 2017, 8, 22313-22324.	1.8	29
8	Therapeutic Targeting ofSDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. Clinical Cancer Research, 2020, 26, 3868-3880.	7.0	29
9	18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1574-1582.	3.6	27
10	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. Journal of Pathology, 2020, 251, 378-387.	4.5	23
11	Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma. Cancers, 2020, 12, 280.	3.7	23
12	The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. Cancers, 2019, 11, 654.	3.7	21
13	Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma. Journal of the National Cancer Institute, 2022, 114, 130-138.	6.3	21
14	Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina. Cancer Research, 2018, 78, 1266-1274.	0.9	16
15	MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment. Neuro-Oncology Advances, 2020, 2, vdaa065.	0.7	16
16	A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2V617F positive polycythemia vera: a case report. BMC Cancer, 2018, 18, 286.	2.6	15
17	Tumor mutational burden and immunotherapy in gliomas. Trends in Cancer, 2021, 7, 1054-1058.	7.4	15
18	Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. International Journal of Cancer, 2020, 146, 2326-2335.	5.1	14

#	Article	IF	Citations
19	Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. Cancers, 2021, 13, 6092.	3.7	14
20	Targeting CDK9 for the Treatment of Glioblastoma. Cancers, 2021, 13, 3039.	3.7	12
21	Ischemia preconditioning protects astrocytes from ischemic injury through 14â€3â€3Î³. Journal of Neuroscience Research, 2015, 93, 1507-1518.	2.9	11
22	Nonmosaic somatic HIF2A mutations associated with late onset polycythemiaâ€paraganglioma syndrome: Newly recognized subclass of polycythemiaâ€paraganglioma syndrome. Cancer, 2019, 125, 1258-1266.	4.1	11
23	C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. Journal of Bone and Mineral Research, 2020, 36, 315-321.	2.8	9
24	Chiari Malformation Type 1 in EPAS1-Associated Syndrome. International Journal of Molecular Sciences, 2019, 20, 2819.	4.1	8
25	Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. Endocrine, 2018, 61, 216-223.	2.3	7
26	Neuraxial dysraphism in EPAS1-associated syndrome due to improper mesenchymal transition. Neurology: Genetics, 2020, 6, e414.	1.9	5
27	Report of Canonical BCR-ABL1 Fusion in Glioblastoma. JCO Precision Oncology, 2021, 5, 1348-1353.	3.0	3
28	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. Frontiers in Oncology, 2020, 10, 601452.	2.8	1